You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Claims for Patent: 8,835,474

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,835,474

Title:	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Abstract:	(R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for overactive bladder.
Inventor(s):	Takasu; Toshiyuki (Tsukubamirai, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsuchiura, JP), Shibasaki; Masayuki (Tokyo, JP)
Assignee:	Astellas Pharma Inc. (Tokyo, JP)
Application Number:	13/117,638
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,835,474
Patent Claims:	1. A method for treating overactive bladder comprising administering an effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or a salt thereof as an active ingredient to a subject in need thereof. 2. The method according to claim 1, wherein said overactive bladder is a result of benign prostatic hyperplasia. 3. The method according to claim 1, wherein said subject has urinary urgency. 4. The method according to claim 1, wherein said subject has urinary incontinence. 5. The method according to claim 1, wherein said subject has pollakiuria. 6. The method according to claim 1, wherein (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or a salt thereof is administered orally. 7. A method for treating overactive bladder comprising administering an effective amount of a free base of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide as an active ingredient to a subject in need thereof. 8. The method according to claim 7, wherein said overactive bladder is a result of benign prostatic hyperplasia. 9. The method according to claim 7, wherein said subject has urinary urgency. 10. The method according to claim 7, wherein said subject has urinary incontinence. 11. The method according to claim 7, wherein said subject has pollakiuria. 12. The method according to claim 7, wherein the free base of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide is administered orally.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.